Latest Conference Articles

As more practices adopt the COME HOME model, they are adapting it to fit their needs, explained Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants. However, some practices may not have the resources to keep up with data collection requirements while ramping up clinical interventions.

Nina Brown-Ashford, MPH, CHES, deputy group director at the CMS Innovation Center, discusses how Medicare’s Diabetes Prevention Program will help improve population health and contain the high costs of diabetes care.

Value-based care strategies will continue to progress no matter who occupies the White House, according to Gail Wilensky, PhD, of Project HOPE. HHS Secretary Tom Price has indicated his support for limited demonstrations, but Wilensky predicts he will continue to push against large-scale mandatory demonstrations.

As practices adopt the Oncology Care Model, practices should consider how this change will influence the practice and make efforts to continue engaging with the staff during this process, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

Material suppliers, manufacturers, pharmacies, and rebate programs all contribute to the rising prices of insulin, according to Alan Carter, PharmD, principal investigator and senior advisor at MRIGlobal, and adjunct faculty at University of Missouri—Kansas City School of Pharmacy.

According to Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review (ICER), patient perspectives are critical for determining meaningful outcomes and helping to guide the cost-effectiveness review process.

According to its CEO and president Michael Griffin, Daughters of Charity is undertaking a number of projects that use technology to improve care coordination and communication.

Differential pricing structures are necessary for products with surrogate endpoints and to account for revolutionizing treatments in order to have a more sustainable value equation, according to Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center.

As a cancer survivor, Rose Gerber, director of patient advocacy for the Community Oncology Alliance, is personally aware of the many long-term issues that can arise during survivorship. These can include physical effects like bone health and emotional issues like the fear of recurrence.

Diabetes patients will be more satisfied with treatment when they perceive benefits and will continue treatment when physicians keep in contact and point out the progress, says William Polonsky, PhD, CDE, president of the Behavioral Diabetes Institute and associate clinical professor at University of California, San Diego.

Real-time prescription benefit transactions are designed to give clinicians essential information on an individual patient’s benefits before writing a prescription, according to Laura Topor, president of Granada Health.

Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine addresses the improvements that are needed in the future of closed-loop systems for diabetes treatment.

As Republicans work to reform Medicaid, they must contend with questions about the appropriate financial support level and the grant structure of the program, according to Gail Wilensky, PhD, of Project HOPE.

Clinicians have obligations of justice when treating patients, which can lead to difficult decisions on how to ethically allocate limited resources to patients as a whole, said Jacqueline Glover, PhD, professor in the Department of Pediatrics and the Center for Bioethics and Humanities at the University of Colorado Denver.

Oncologists envision a move towards using data to become a learning health system, which is aided by the changing landscape emphasizing quality and value, explained Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health.

Value-based price benchmarks can help payers determine whether a drug’s price aligns with its ability to help patients, which can then facilitate the innovation and uptake of new therapies, said Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review (ICER).

Nearly 12 years after Hurricane Katrina caused devastating damage and flooding in New Orleans, the city has still not completely recovered, although there is now a stronger infrastructure for primary care, according to Michael Griffin, president and CEO of Daughters of Charity Services.

The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.

Glytec’s Glucommander electronic glucose management system (eGMS) helped the Kaweah Delta hospital shift its standard of care to basal-bolus insulin, explained Raymie McFarland, vice president of Quality Initiatives at Glytec. Basal-bolus is considered best practice and is safer for patients, but many hospitals have not adopted it due to its difficulty. Glytec hopes its eGMS can change that.

Constraining the cost of prescription drugs is a politically popular idea, but the same objective might be accomplished through evidence-based decision support for setting appropriate drug prices, according to Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.

There are some areas in health policy where Democrats and Republicans can find common ground, like incentivizing greater value, but bipartisan talks won’t happen while there are still active efforts to repeal the Affordable Care Act, said David M. Cutler, PhD, of Harvard University.

The uncertainty in the political climate, along with the limited authority of the Health Resources and Services Administration within HHS, makes it difficult to predict whether the 340B program will be reformed in coming years, according to Leah Ralph, director of health policy at the Association of Community Cancer Centers.

Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses determining cost effectiveness of novel treatments, such as immuno-oncology agents, and potential solutions to reducing financial toxicity in cancer care.

As the Institute for Clinical and Economic Review (ICER) prepares to update its final value proposal framework, it has been aided by the constructive comments from different stakeholders, said ICER president Steve Pearson, MD, MSc. He predicts that coming years will see continued interest in how to utilize such frameworks.

Working with real-world evidence-based data can pose difficulties, both when collecting and analyzing the information, but redesigned incentives could help drive entities to provide more information, said Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington.

While the political landscape is changing and new policies are being debated, lawmakers of both political parties can agree on the common goal of improving disease management for costly patients with complex health needs, according to Sachin H. Jain, MD, MBA, president and CEO of CareMore.

All stakeholders stand to gain from the 340B program in different ways, but they also take on different risks, like the potential impact for health plans on rebate contracts, said Neil Minkoff, MD, chief medical officer of EmpiraMed.

The main value of the COME HOME model for oncology practices is that it can help reduce hospitalization rates, leading to better quality of life for patients and clinicians, according to Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.